# TXP Medical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/txp-medical-co

- Industry: Healthcare
- Headquarters: Tokyo, Japan
- Website: www.txpmedical.jp
- Total disclosed funding: $14M
- Latest round: Series C (Oct 23, 2024)
- Investors on record: 5

## About

TXP Medical Co., Ltd. is a Tokyo-based company specializing in advanced medical data solutions that enhance decision-making in healthcare environments to improve patient outcomes and operational efficiency.Founded in 2017 in Tokyo, Japan, TXP Medical Co., Ltd. delivers innovative medical data solutions. The company has completed a total of 4 deals to date, with its latest funding event being a Series B round that raised JPY 1.5 billion in 2024. Notably, the company received investments from Itochu and The University of Tokyo Edge Capital Partners. The firm’s current valuation stands at JPY 7,058.734 million.TXP Medical???? specializes in advanced medical data solutions designed to enhance decision-making in complex healthcare environments. The company's core offerings include the NEXT Stage series, encompassing products like NEXT Stage ER, a system for emergency departments in acute care hospitals; NEXT Stage ICU, which provides a dashboard for managing intensive care unit patient information; and NEXT Stage CONNECT, aimed at facilitating seamless transfer of patients between medical institutions. These solutions utilize technology to connect fragmented medical data, enabling more efficient operations and improved patient outcomes in emergency and critical care settings. TXP Medical serves a diverse clientele, including hospitals, emergency medical services, and healthcare professionals primarily in Japan but also targeting international markets seeking enhanced medical data integration and analytics capabilities.TXP Medical's revenue model is structured around subscription-based services and direct partnerships with healthcare providers. Clients typically engage with the company to implement its suite of products, which may involve initial setup fees along with ongoing subscription costs for software usage and updates. The flagship products, such as NEXT Stage ER and NEXT Stage ICU, are integral to the operational workflows of their users, leading to recurring revenue through annual or multi-year contracts. Additionally, the company may explore collaborative arrangements with pharmaceutical firms for clinical research services, further diversifying its revenue streams while enhancing patient care through data-driven solutions.In October 2024, TXP Medical Co., Ltd. raised JPY 2.4 billion in Series C funding from new investors MPower Partners, NTT Communications Corporation, and Medical Data Vision Co., Ltd. This funding includes venture debt aimed at enhancing healthcare data utilization, expanding services, developing AI solutions, and strengthening organizational capabilities for future growth. The company is expected to launch new products designed to improve data integration and analytics capabilities by 2025 and plans to expand its services into international markets, focusing on regions seeking advanced medical data solutions.

## Funding rounds

- Series C, Oct 23, 2024 — NTT Communications Corporation, MPower Partners, Medical Data Vision Co., Ltd.
- Series B, Apr 5, 2022, $12M — University of Tokyo Edge Capital Partners, Itochu
- Series A, Nov 29, 2020, $2.4M — University of Tokyo Edge Capital Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B
- Itochu — Series B
- NTT Communications Corporation — Series C
- MPower Partners — Series C
- Medical Data Vision Co., Ltd. — Series C